Importantly, through pharmacological and dietary interventions that target GC-KLF15-BCAA signaling, we were able to significantly improve disease phenotypes in 2 distinct SMA mouse models (Fig. 9). The gene discussed is KLF15; the disease is proximal spinal muscular atrophy.